Police in New Jersey were contacted about the alleged harassment as it escalated around Christmas, Retrophin settled a lawsuit against the ex-worker out of court, confidentially, in early 2014 after the employee's lawyer asked a New York judge to order Shkreli's computers to be analyzed on the heels of the allegations.



Retrophin's board later move to replace Shkreli as CEO, and he resigned his positions. Retrophin is now suing him for $65 million in a case where he is accused of acting against the interests of the company.

Shkreli, through a spokesman, declined to comment for this story. Pierotti's lawyer declined to comment, citing a confidentiality agreement.

A Retrophin spokesman, when asked for comment, said: "Retrophin's claims regarding Mr. Shkreli are detailed in the company's lawsuit against him. The company's leadership is focused on running and growing the business and will make its arguments on this matter in court or in arbitration, as appropriate. The Pierotti litigation was brought and settled under Mr. Shkreli's tenure, and we have no further comment on the matter."

Shkreli made headlines this week when it was revealed that his current company Turing Pharmaceuticals, had hiked the price of Daraprim from $13.50 to $750 per pill after Turing bought the drug, which is used to treat a parasitic infection, in August.

The move, which Shkreli has defended as necessary for Turing to be profitable and to fund research for a replacement drug, drew widespread criticism, with Clinton calling the move "outrageous." Clinton's comment, and her vow to introduce a plan to control drug prices overall, sent biotech stocks plummeting Monday.

Shkreli, a former hedge fund manager, had been fired from Retrophin, which he founded, last year. In August, the company sued him in Manhattan federal court, for "repeatedly breaching his duty of loyalty to Retrophin," by allegedly using his control of Retrophin to "enrich himself and to pay off claims of [his prior hedge fund's] investors (who he had defrauded)," Retrophin claimed in its suit.

"Shkreli was the paradigm faithless servant," Retrophin charged in its suit, which is seeking $65 million in damages from its founder.

Shkreli has denied Retrophin's claims, and has asked that the dispute be settled in arbitration. He told The New York Times that Retrophin owes him at least $25 million in severance, and that "they are sort of concocting this wild and crazy and unlikely story to swindle me out of the money."